Tetanus occupies an unusual place in the modern medical imagination — it's old enough to feel solved, yet its causative toxin remains one of the most lethal biological substances known. When immunization coverage slips, this ancient disease does not stay dormant. The JAMA Network viewpoint draws attention to a troubling pattern: tetanus is returning in populations where vaccine uptake has waned, challenging the assumption that near-elimination equals permanent control.
Clostridium tetani, the spore-forming bacterium behind tetanus, produces tetanospasmin, a neurotoxin that blocks inhibitory neurotransmitter release, causing the characteristic sustained muscular rigidity and spasms. Unlike many vaccine-preventable diseases, tetanus confers no lasting natural immunity after infection — survivors remain susceptible without subsequent vaccination. The toxoid vaccines (Td, Tdap) function by generating antibody-mediated neutralization of the toxin before it binds irreversibly to neural tissue. Critically, protective antibody titers wane over roughly a decade, meaning booster adherence is not optional for sustained protection. Case surveillance data highlighted in the piece point to increased incidence in under-vaccinated adult cohorts and regions where healthcare infrastructure has been disrupted.
This viewpoint lands at a moment when vaccine hesitancy research consistently shows tetanus is paradoxically among the vaccines adults feel least urgency about — partly because its clinical threat is perceived as remote. Yet tetanus case fatality rates in low-resource settings remain between 10–80%, and even in high-income countries with intensive care, mortality approaches 10–20% for severe cases. The biology here leaves little margin: once tetanospasmin binds to presynaptic nerve terminals, no antitoxin can reverse it. From a population-health standpoint, this is a confirmatory rather than paradigm-shifting piece, but its publication in JAMA signals warranted concern. The primary limitation is its viewpoint format — it synthesizes existing evidence without presenting new primary data. Still, the policy and clinical reminder it delivers is timely and grounded in durable immunological science.